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ABSTRACT Mutations in the gene that encodes the cystic ﬁbrosis transmembrane conductance regulator (CFTR) cause cystic
ﬁbrosis. TheCFTRanion channel is controlled byATPbinding andenzymatic activity at the twonucleotide-binding domains.CFTR
exhibits two types of enzymatic activity: 1), ATPase activity in the presence of ATPand 2), adenylate kinase activity in the presence
of ATP plus physiologic concentrations of AMP or ADP. Previous work showed that P1,P5-di(adenosine-59)pentaphosphate
(Ap5A), a speciﬁc adenylate kinases inhibitor, inhibited wild-type CFTR. In this study, we report that Ap5A increased activity of
CFTRwith anL1254Amutation. Thismutation increased theEC50 for ATPby.10-fold and reduced channel activity by prolonging
the closed state. Ap5A did not elicit current on its own nor did it alter ATP EC50 or maximal current. However, it changed the
relationship between ATP concentration and current. At submaximal ATP concentrations, Ap5A stimulated current by stabilizing
the channel open state. Whereas previous work indicated that adenylate kinase activity regulated channel opening, our data
suggest that Ap5A binding may also inﬂuence channel closing. These results also suggest that a better understanding of the
adenylate kinase activity of CFTR may be of value in developing new therapeutic strategies for cystic ﬁbrosis.
INTRODUCTION
The cystic ﬁbrosis transmembrane conductance regulator
(CFTR) forms an anion channel expressed primarily in epi-
thelia (1–4). Like other ATP-binding cassette (ABC) trans-
porters, CFTR contains two nucleotide-binding domains
(NBDs) and two membrane-spanning domains (MSDs). In
addition, it contains a regulatory (R) domain. Among ABC
transporters, CFTR is unique because it forms a channel
through which anions ﬂow passively, driven in either direc-
tion by the electrochemical gradient across the membrane.
Activity of the CFTR anion channel requires kinase-medi-
ated phosphorylation of the R domain (1,2,5). The binding of
ATP to the NBDs and their enzymatic activity then open and
close the channel. Structural evidence fromotherABCproteins
indicates that the two NBDs form a complex in a rotationally
symmetric head-to-tail dimer (6–8). TheNBDdimers form two
ATP-binding sites; each ATP is sandwiched between the
Walker A motif (the P-loop) of one NBD and the signature
(LSGGQ)motif of the other NBD. InCFTR,ATP-binding Site
1 includes theWalkerAmotif ofNBD1 and the signaturemotif
of NBD2. The Walker A motif of NBD2 and the signature
motif of NBD1 contribute to ATP-binding Site 2.
Both ATP-binding sites control channel opening and
closing (9–12). The interaction of ATP with Site 1 is required
for normal gating. When mutations prevent ATP from
binding to Site 2, ATP-binding Site 1 can gate the channel,
albeit with reduced activity (11). Normal gating also requires
the interaction of ATP with ATP-binding Site 2, and the
majority of the enzymatic activity of CFTR occurs at this site
(9,13–15). Previous work showed that CFTR NBDs possess
the capacity for two different kinds of enzymatic activity. In
the presence of ATP alone, ATPase activity (Mg21 ATP/
Mg21 1 Pi 1 ADP) is required for channel gating (1,2,5).
This observation is consistent with the ATPase activity re-
ported for several other ABC transporters (16). However,
when ATP is added in the presence of physiologic concen-
trations of AMP, adenylate kinase activity (Mg21ATP 1
AMP D Mg21ADP1 ADP) regulates channel activity (17–
20). The two enzymatic activities (ATPase and adenylate
kinase) appear to share an ATP-binding site — ATP-binding
Site 2. Adenylate kinase activity has been described in iso-
lated CFTR NBDs by several groups (17,18,21), and mixing
NBD1 and NBD2 caused a synergistic enhancement of
adenylate kinase activity (20). However, another study (21)
reported no synergistic or additive effects on adenylate ki-
nase activity when combining NBD1 and NBD2. In addition,
that study failed to detect adenylate kinase activity after
solubilization of recombinant CFTR from membranes, al-
though the adenylate kinase inhibitor P1,P5-di(adenosine-
59)pentaphosphate (Ap5A) inhibited Cl
 transport when
CFTR was reconstituted into membranes (21). The reason for
these discrepancies remains unclear. Interestingly, another
recent report (22) indicates that a different ABC protein,
Rad50, also functions as ATPase and as an adenylate kinase.
Although structural and functional studies have ascertained
where ATP binds in the NBDs of ABC transporters, the
distinct AMP-binding site in CFTR has not been identiﬁed.
The goal of this study was to better understand how ade-
nylate kinase activity controls CFTR. As a probe of adenylate
kinase,weusedAp5A,which is a speciﬁc inhibitor of adenylate
kinases and known to bind simultaneously to the ATP-binding
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site and the AMP-binding site (23–25). Previous studies
showed thatAp5A also inhibitsCFTRadenylate kinase activity
and channel gating (17,18,20). We asked whether the inhibi-
tory effect of Ap5A would be reduced or eliminated by point
mutations in the NBDs. We made a series of mutations, se-
lecting residues based on the crystal structure of ATP bound to
an NBD homodimer (7). Because ATP sits at the interface
between the twoNBDs, because bothNBDs contribute toATP
binding, and because dimerization of the two NBDs may reg-
ulate gating, we chose residues in or near the dimer interface.
Then, we tested the inhibitory effect of Ap5A applied to the
cytosolic surface of the variant CFTR channels.
EXPERIMENTAL PROCEDURES
Site-directed mutagenesis and cell
expression systems
CFTR mutants were prepared in the pTM1-CFTR4 plasmid using Quik-
Change site-directed mutagenesis (Stratagene, LaJolla, CA). We determined
the correct identity of each mutant by sequencing the entire cDNA. Wild-
type and mutant CFTR proteins were transiently expressed in HeLa cells
using the vaccinia virus/T7 expression system as described previously (26).
For some studies, CFTR was transiently expressed in HeLa cells using the
pIRES-EGFP vector (27) so that we could identify transfected cells by en-
hanced green ﬂuorescent protein (eGFP) ﬂuorescence.
Patch-clamp studies
We used excised, inside-out membrane patches. The pipette (extracellular)
solution contained 140 mM N-methyl-D-glucamine, 100 mM L-aspartic
acid, 3 mMMgCl2, 5 mM CaCl2, and 10 mM tricine (pH 7.3) with HCl; the
ﬁnal Cl concentration was ;51 mM. The bath (intracellular) solution
contained 140 mM N-methyl-D-glucamine, 3 mM MgCl2, 1 mM CsEGTA
(cesium ethylene glycol bis(2-aminoethyl ether)-N,N,N9,N9-tetraacetic acid),
and 10 mM tricine (pH 7.3) with HCl; the ﬁnal Cl concentration was 140
mM. After patch excision, channels were activated with the catalytic subunit
of cAMP-dependent protein kinase (PKA, 80 U/mL; Promega,Madison,WI)
and ATP. Unless otherwise speciﬁed, PKA was present in all cytosolic so-
lutions that contained ATP. All nucleotides and inhibitors were purchased
from Sigma-Aldrich (St. Louis, MO). ATP was added as the Mg21 salt. The
cytosolic surface of patches was continuously perfused with a multichannel
rapid change perfusion system. Holding voltage was 40 mV for macro-
patch experiments and 50 to 100 mV for single-channel experiments.
Experiments were performed at temperatures between 23 and 26C.
An Axopatch 200B ampliﬁer (Axon Instruments, Union City, CA) was
used for voltage clamping and current recording, and the pCLAMP software
package (version 9.1; Axon Instruments) was used for data acquisition and
analysis. Data were digitized at 5 kHz. Macroscopic current recordings were
low-pass ﬁltered at 100 Hz using an 8-pole Bessel ﬁlter (Model 900; Fre-
quency Devices, Haverhill, MA), and single-channel recordings were low-
pass ﬁltered at 500 Hz for analysis and at 10 or 50 Hz for display in the
accompanying Figures. Single-channel analysis was performed as previously
described (9,28), with a burst delimiter of 20 ms. Events # 4 ms duration
were ignored.
Data are presented as mean 6 SE. p values ,0.05 were considered sta-
tistically signiﬁcant.
Ap5A puriﬁcation
We tested whether Ap5A was contaminated with other nucleotides. High-
performance liquid chromatography (HPLC) revealed low levels of ATP,
ADP, and AMP (Fig. 1 A). Quantitative measurements indicated that 1 mM
Ap5A contained ;2 mM ATP and that the amount varied from lot to lot.
Therefore, we puriﬁed Ap5A for some experiments. Before HPLC puriﬁ-
cation, the Ap5A preparation (10 mg/mL) was treated with hexokinase (100
U/mL) in the presence of 100 mM glucose/phosphorylate glucose using the
g-phosphate of any ATP present to generate glucose 6-phosphate and ADP.
HPLC was performed on a System Gold microbore HPLC system with an
anion exchange column-Q column (4.6 3 100 mm, 10 mm particle size)
using 32 Karat software (Beckman Coulter, Fullerton, CA). Solution A was
10 mM TEAB (triethyl-ammonium bicarbonate), and solution B was 1 M
TEAB (pH 7.5). A 2 mg sample was injected, detected at 254 nm, and
collected. The collected sample was frozen at 80C and then lyophilized.
Puriﬁed Ap5A (Fig. 1 B) was dissolved in double-deionized H2O to ;50
mM, and the absorbance of the solution was measured at 260 nm to calculate
the concentration. We obtained similar functional results with puriﬁed and
nonpuriﬁed Ap5A.
RESULTS
Ap5A inhibited wild-type CFTR but
stimulated CFTR-L1254A
We generated 29 variants in which alanine or another amino
acid replaced a residue in NBD2 or NBD1. Fig. 2 shows
locations of residues homologous to those we tested high-
lighted in the dimer structure of the ABC transporter MJ0796
(7). We used MJ0796 because it has a clear NBD dimer
FIGURE 1 HPLC of Ap5A before (A) and after (B) puriﬁcation. Peaks
were identiﬁed based on elution times of ATP, ADP, and AMP standards.
The peaks around elution time 12 min and between 50 to 60 min are artifacts
due to solution changes.
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structure, whereas the dimer structure of CFTRNBD1/NBD2
is not known.
We phosphorylated CFTR with PKA and studied current
in the presence of 75 mM ATP; our previous work showed
that 1 mM Ap5A inhibited current by ;50% with this con-
centration of ATP (18). As we previously reported, adding
1 mM Ap5A to the cytosolic surface of excised, membrane
patches inhibited wild-type CFTR current (Fig. 3, A and B).
In all but one of the variants, Ap5A inhibited current, similar
to what we observed in wild-type CFTR. Surprisingly, the
L1254A mutation reversed the effect of Ap5A, so that Ap5A
stimulated CFTR current. When added alone to phosphory-
lated wild-type CFTR (18) or CFTR-L1254A (Fig. 4), Ap5A
did not generate activity.
Ap5A changed the ATP-dependence
of CFTR-L1254A
To better understand ATP-dependent regulation of the
L1254A variant, we examined the relationship between ATP
concentration and current (Fig. 5, A and B). The L1254A
mutation did not signiﬁcantly change the shape of the curve;
the Hill coefﬁcient was 1.066 0.08 for wild-type CFTR and
0.92 6 0.06 for CFTR-L1254A, although the two lowest
ATP concentrations were not well ﬁt by the regression line.
However, introduction of the L1254A mutation shifted the
relationship between ATP concentration and current to the
right, increasing the ATP EC50 from 346 3mM in wild-type
CFTR to 392 6 38 mM in CFTR-L1254A (p , 0.05). In
addition, the activity of CFTR-L1254A was not completely
saturated at 10 mM ATP. These results suggest that the
L1254A mutation may have impaired the interaction with
ATP.
In wild-type CFTR, Ap5A did not alter the level of max-
imal current, but it increased the EC50 for ATP and the Hill
FIGURE 2 The dimer structure of the ABC transporter MJ0796 (7). For
purposes of illustration, we represent the left side as NBD1 (green) and the
right side as NBD2 (blue). Both Walker A motifs are in dark blue, and both
LSGGQmotifs are in brown. Two ATP molecules are shown as stick shapes
(oxygen is in red and phosphate in orange). The residue analogous to Leu-
1254 in CFTR is Leu-48 in MJ0796; it is shown in red as a space-ﬁlling
structure. Other tested residues are shown in yellow as stick structures.
FIGURE 3 Effect of Ap5A on wild-type and mutant CFTR Cl
 currents.
(A) Representative time course of Cl current (I) in response to application
of the indicated agents on wild-type CFTR and CFTR-L1254A. Data are
from excised, inside-out patches containing multiple channels. The dashed
lines indicate average current levels at the various conditions. (B) Data from
all the tested mutations (N $ 3 for each). The ATP concentration was 75
mM, and the Ap5A concentration was 1 mM. Asterisk indicates p , 0.05
compared to wild-type CFTR using the Mann-Whitney rank sum test. It is
possible that testing a larger number of membrane patches would show that
Ap5A inhibited some variants to a statistically greater degree than wild-type
CFTR. Our goal, however, was to ﬁnd mutations that reduced inhibition, and
so we did not study most variants further.
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coefﬁcient decreased from 1.02 6 0.04 to 0.63 6 0.04 (18).
With CFTR-L1254A, we found that 1 mM Ap5A had no
signiﬁcant effect on the EC50 (369 6 100 mM) or the pre-
dicted current at maximal ATP concentrations (Fig. 5, A and
B). However, Ap5A changed the shape of the curve; the Hill
coefﬁcient decreased to 0.58 6 0.06 (p , .05). Thus, Ap5A
reduced the Hill coefﬁcient to ,1 in wild-type and L1254A
CFTR suggesting conformational changes associated with
negative cooperativity.
CFTR-L1254A interacts with AMP and
other nucleotides
We tested several other agents to learn how the L1254A
mutation affected function. In the presence of ATP, AMP
induces adenylate kinase activity in isolated CFTR NBDs
(17,18,20,21), and it induces gating that is dependent on
adenylate kinase activity in CFTR (18). Previous studies also
showed that ADP inhibits CFTR current (29,30), at least in
part through its effect on adenylate kinase activity (19). We
found that, as with wild-type channels, AMP stimulated and
ADP inhibited current from the L1254A mutant (Fig. 6, A
and B). These results suggest that the L1254A mutation did
not completely disrupt the AMP-binding site in CFTR.
To further examine the functional consequences of the
CFTR-L1254A mutation in the region around ATP-binding
Site 2, we examined the effect of AMP-PNP and pyro-
phosphate (PPi). AMP-PNP is a nonhydrolyzable analog of
ATP that increases current by delaying channel closure
(9,15,31–33). Previous data showed that mutations that
disrupt ATP-binding Site 2 prevented its stimulatory effect,
although some biochemical data suggest that AMP-PNP
may interact with ATP-binding Site 1 (13). Mutations
around ATP-binding Site 2 can also prevent the stimulatory
effects of PPi (14,34,35). We found that the L1254A mu-
tation did not prevent the stimulatory effects of AMP-PNP
or PPi (Fig. 6, C and D) and that stimulation was greater in
CFTR-L1254A than in wild-type CFTR, perhaps because
the basal activity before adding these agents was lower in
CFTR-L1254A. These results suggest that the L1254A
mutation did not completely disrupt the area around ATP-
binding Site 2.
Ap5A stabilized the open state of CFTR-L1254A
To determine how Ap5A increased CFTR-L1254A current at
low ATP concentrations, we removed ATP and measured the
rate at which current decreased, that is, the relaxation rate. In
wild-type CFTR, current decreased with a rate constant of
11956 418 ms (Fig. 7, A and B). Ap5A had no effect on the
rate (1596 6 430 ms; p . 0.05). In contrast, in CFTR-
L1254A, Ap5A nearly doubled the time constant for current
decay (1657 6 565 ms without Ap5A, 3161 6 948 ms with
Ap5A; p , 0.01). This result suggested that Ap5A may have
FIGURE 4 Effect of Ap5A on current of CFTR-L1254A. Data are a
tracing of a membrane patch perfused on the cytosolic surface with 1 mM
puriﬁed Ap5A alone, with 75 mM ATP alone, or with 75 mM ATP plus
1 mM puriﬁed Ap5A. Channel was preactivated with PKA and 2 mM ATP.
Adding Ap5A alone yielded a failure to activate CFTR-L1254A in ﬁve other
experiments.
FIGURE 5 Effect of ATP concentration on current of wild-type CFTR
(WT, red) and CFTR-L1254A in the absence (black) and presence (blue) of
1 mM Ap5A. Because each patch contained a different number of CFTR
channels, all currents were normalized to the current obtained with 1 mM
ATP in the absence of Ap5A. Data are plotted as (I/I1mM ATP) in panel A or as
a Hill plot in panel B. For wild-type CFTR, the Hill coefﬁcient was 1.06 6
0.08, the Km¼ 346 3 mM, and the Imax¼ 1.016 0.02. For CFTR-L1254A,
the Hill coefﬁcient was 0.926 0.06, the Km¼ 3926 38 mM, and the Imax¼
1.33 6 0.04. For CFTR-L1254A studied with 1 mM Ap5A data, the Hill
coefﬁcient was 0.586 0.06, the Km¼ 3696 100 mM, and the Imax¼1.456
0.09. Data are from 30 patches; n $ 3 for each ATP concentration.
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stabilized the open state and predicted that Ap5A would in-
crease the burst duration of CFTR-L1254A.
In excised, inside-out patches of membrane, CFTR-
L1254A showed reduced channel activity compared to wild-
type CFTR. The Po was 0.03 6 0.01 (Fig. 8, A and B)
compared with values of 0.15 6 0.02 for wild-type CFTR
obtained in recent studies from our laboratory under the same
conditions (75 mM ATP) (18). A longer interburst interval
(32.56 11.6 s compared to 2.46 0.27 s for wild-type CFTR
(18)) reduced the Po of CFTR-L1254A. However, the effect
of the reduced opening rate on the Po was partly countered
by a prolonged burst duration (870 6 204 ms compared to
427 6 18 ms for wild-type CFTR (18)).
Adding 1 mMAp5A to CFTR-L1254A increased the Po by
increasing the burst duration ;40% (from 870 6 204 ms to
12146 281 ms; p, 0.05) without a signiﬁcant effect on the
interburst interval (from 32.56 11.6 s to 32.96 13.9 s; p.
0.05) (Fig. 8, A and B). These results support the conclusion
that Ap5A stabilized the open state. These ﬁndings are also
very different from data obtained with wild-type CFTR in
which Ap5A had no signiﬁcant effect on the burst duration
but prolonged the interburst interval (18).
DISCUSSION
In all of the CFTR variants that we examined, Ap5A altered
current. However, we were surprised to observe that Ap5A
increased current from one of the variants, L1254A; this
ﬁnding is the opposite of the effect of Ap5A on wild-type
CFTR (18).
Several observations suggest that the AMP-binding site
remained available in CFTR-L1254A. First, Ap5A altered
CFTR-L1254A current. Our previous work on wild-type
CFTR (18) and studies on other adenylate kinases (24,36)
indicate that the ability of Ap5A to alter function depends on
FIGURE 6 Effect of AMP (A), ADP (B),
AMP-PNP (C), and PPi (D) on wild-type
CFTR and CFTR-L1254A. Data are from ex-
cised, inside-out patches containing multiple
CFTR channels. For each patch, data are nor-
malized to current before addition of the test
agent. Zero indicates no change. In A, N¼ 9 for
wild-type CFTR and N ¼ 15 for CFTR-
L1254A; in B, N ¼ 4 for wild-type and N ¼ 8
for L1254A; in C, N ¼ 3 for wild-type and
L1254; and inD, N¼ 5 for wild-type and N¼ 3
for L1254A. Data are individual values and
means 6 SE. Asterisk indicates p , 0.05 by
t-test. Tracings on right show examples.
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its simultaneous binding to the ATP- and AMP-binding sites.
Second, AMP stimulated CFTR-L1254A current in the
presence of ATP. This result is similar to the stimulation of
wild-type CFTR (18). Third, ADP inhibited CFTR-L1254A
current. Earlier studies showed that ADP inhibits CFTR
function, at least in part via an effect on adenylate kinase
activity involving ATP-binding Site 2 and the AMP-binding
site (19).
The data also indicate that the L1254A variant altered the
interaction with ATP. The observation most supportive of
this conclusion was a 10-fold increase in EC50 for ATP-
dependent stimulation. In addition, the mutation reduced the
channel opening rate (increased the interburst interval); this
step in the gating process is the one that is most dependent
on ATP concentration (15,32,37). Studies of NBD crystal
structures from related ABC proteins are also consistent with
the conclusion that the L1254A mutation altered the inter-
action with ATP. Although residues corresponding to Leu-
1254 itself do not interact directly with ATP, they do form
hydrogen bonds to the Lys and Ser/Thr residues in the
Walker A motif and to the Asp in the Walker B motif (6–
8,38). These residues interact with ATP. In addition, these
residues are important for gating (9,39–41) and for enzymatic
activity (5,16,42). Our ﬁnding that CFTR-L1254A had a
prolonged burst duration is consistent with a reduced enzy-
matic activity associated with mutating those residues.
How did Ap5A stimulate CFTR-L1254A current? We
speculate the following: 1), ATP binds ATP-binding Site 1 as
it does in wild-type CFTR. Our data showing that Ap5A only
affects gating in the presence of ATP, combined with our
earlier studies (18), suggest that the L1254A mutation does
not disrupt ATP binding at Site 1. The predicted structure of
the NBDs is also consistent with this conclusion because
L1254 has hydrogen bonds only to other residues in NBD2;
these hydrogen bonds are in the region of ATP-binding Site 2
and not in ATP-binding Site 1 or NBD1 (7,38). 2), The
L1254A mutation partially disrupts ATP binding at Site 2.
This speculation is supported by the reduced opening rate, the
prolonged burst duration, and the 10-fold increase in ATP
EC50 without a change in the shape of the relationship be-
tween ATP concentration and current. These changes are
similar to those produced by other mutations thought to
partially disrupt ATP-binding Site 2. For example, the
K1250A and D1370Nmutations also have a reduced opening
rate, prolonged burst duration, and increased ATP EC50
(11,12,14,15,29,32,39,43). It seems unlikely that the
L1254A mutation completely eliminates ATP binding at Site
2 because the mutation increased burst duration, whereas
mutations that eliminate ATP binding at Site 2 do not
increase burst duration (11,14,28). 3), Ap5A binds to ATP-
binding Site 2. We cannot exclude Ap5A binding to ATP-
binding Site 1; if that were the case, however, ATP would
also have to bind to ATP-binding Site 2 because Ap5A cannot
open CFTR channels on its own. Why would the L1254A
mutation reduce the afﬁnity for ATP but allow Ap5A to bind?
We speculate that Ap5A has a greater afﬁnity in this mutant
because it binds at two sites. Moreover, Ap5A binding in
adenylate kinases induces conformational changes that may
enhance its binding afﬁnity (23,44,45), and perhaps this oc-
curs in CFTR-L1254A. 4), We speculate that Ap5A binding
to CFTR-L1254A generates a more stable open state because
Ap5A is not a substrate for ATPase or adenylate kinase ac-
tivity. Similar behavior is observed with the nonhydrolyzable
FIGURE 7 Current decay after removal of ATP or ATP plus Ap5A. (A)
Representative time course after removal of ATP and Ap5A. Red dotted line
shows the curves ﬁt by an exponential function. (B) Mean decay rates after
removal of ATP or ATP plus Ap5A. N ¼ 5 for both wild-type CFTR and
CFTR-L1254A. As an additional test, we examined current decay after
removing ATP but leaving Ap5A in the solution. In those experiments,
Ap5A prolonged the relaxation rate for CFTR-L1254A (1536 57%; N¼ 5;
p , 0.05) but not for wild-type CFTR (30 6 42%; N ¼ 5).
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ATP analog AMP-PNP, which prolongs the burst duration
(9,15,31–33). In addition, Ap5A may have a slower off-rate
than ATP if it binds two sites.
Although L1254A is not a mutation that causes disease, it
does reduce CFTR function. The ﬁnding that Ap5A enhances
the function of this mutant, whereas it inhibits the function of
wild-type CFTR, suggests the possibility that agents might be
developed that could target unique cystic ﬁbrosis-associated
mutants. These data also suggest that using knowledge about
the adenylate kinase activity of CFTR may be of value in
developing new therapeutic strategies.
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